Pipeline

Synergy IMT groundbreaking therapeutics with potential as standalone or combination therapy to treat a broad range of cancers

Our Pipeline

Synergy IMT is committed to progressing an initial candidate into clinical studies and forming collaborations around other candidates

SYN220

An antibody drug conjugate (ADC) that targets an antigen identified at Synergy IMT that is broadly expressed on different tumor types including colon, breast, gastric and pancreatic. A tumor antigen that was selected for direct tumor cytotoxicity, and rationale for anti-metastatic and anti- protumor microenvironment activity.

SYN120

A bispecific T cell engaging antibody that targets a solid tumor antigen identified at Synergy IMT. A tumor antigen that was selected for direct tumor cytotoxicity, for potential anti-metastatic and anti- protumor microenvironment activity

SYN320

Several multispecific recombinant proteins with anti-tumor activity have been designed to target sTA.

Recombinant Protein Therapeutic
Colon Tumor Xenograft Study
Dosed IV @0.5mg/kg